CanSino vaccine: 90.07% efficacy in serious diseases

CanSino Biologics Inc.‘s vaccine (Ad5-nCoV) is 90.07% effective in preventing serious illness 28 days after single-dose Covid-19 vaccination.

Likewise, the percentage increases to 95.47% in the prevention of serious diseases 14 days after the single dose vaccination.

Based in Tianjin, China, CanSino is a vaccine company that was founded in 2009 by Yu Xuefeng, Zhu Tao, Qiu Dongxu, and Helen Mao Huihua.

Also related to Covid-19, interim analysis data from the Ad5-nCoV phase III clinical trial showed that Ad5-nCoV has an overall efficacy of 65.28% in preventing all symptomatic diseases 28 days after single dose vaccination and 68.83% to prevent all symptomatic diseases 14 days after single-dose vaccination.

The efficacy of Ad5-nCoV has complied with the relevant technical standards established by the World Health Organization (WHO) and the relevant standards and requirements established in “Guiding Principles for the Clinical Evaluation of Preventive Vaccines Against the New Coronavirus

CanSino

In March 2020, Ad5-nCoV was approved for clinical trial after review of registration documents, and the company conducted the phase I clinical trial immediately after such approval.

Then, in April 2020, based on preliminary safety data from the phase I clinical trial for Ad5-nCoV, the phase II clinical trial for Ad5-nCoV was initiated.

Research results from phase I and phase II clinical trials for Ad5-nCoV were published in May 2020 and July 2020, respectively.

In September 2020, CanSino began the global multicenter phase III clinical trial for Ad5-nCoV in five countries, including Pakistan, Mexico, Russia, Chile, and Argentina.

Finally, in February 2021, the company completed the backlog of cases for the interim analysis of the phase III clinical trial of Ad5-nCoV and the data from these cases was sent to the IDMC for analysis and recommendation.

Ad5-nCoV has successfully met its pre-specified primary safety and efficacy criteria in this interim analysis.

There were no serious adverse events related to the vaccine, and therefore the company was able to continue advancing the phase III clinical trial of Ad5-nCoV.

As revealed in the CanSino announcement dated February 24, 2021, the company has completed the vaccination of more than 40,000 volunteers and interim data analysis.

The company is developing 16 candidate vaccines for 13 disease areas.

In February 2021, Ad5-nCoV received the emergency use authorization from Cofepris in Mexico.